Preliminary study: Breast cancers can be well seen on 3T breast MRI with a half-dose of gadobutrol.
| Publication Type | Academic Article |
| Authors | Melsaether A, Kim E, Mema E, Babb J, Kim S |
| Journal | Clin Imaging |
| Volume | 58 |
| Pagination | 84-89 |
| Date Published | 06/27/2019 |
| ISSN | 1873-4499 |
| Keywords | Breast Neoplasms, Contrast Media, Magnetic Resonance Imaging, Mammography, Organometallic Compounds |
| Abstract | BACKGROUND: Dynamic contrast enhanced (DCE) breast MRI is highly sensitive for breast cancer and requires gadolinium-based contrast agents (GBCA)s, which have potential safety concerns. PURPOSE: Test whether breast cancers imaged by 3T DCE breast MRI with 0.05 mmol/kg of gadobutrol are detectable. METHODS: Analysis of 3T DCE breast MRIs with half dose of gadobutrol from patients included in an IRB-approved and HIPPA-compliant prospective study of breast PET/MRI. Between 11/7/2014 and 3/2/2018, 41 consecutive women with biopsy-proven breast cancer that was at least 2 cm, multi-focal or multi-centric, had axillary metastasis, or had skin involvement who gave informed consent were included. Two breast radiologists independently recorded lesion conspicuity on a 4-point scale (0 = not seen, 1 = questionably seen, 2 = adequately seen, 3 = certainly seen), and measured the lesion. Size was compared between radiologists and with size on available mammogram, ultrasound, MRI, and surgical pathology. Inter-reader agreement was assessed by kappa coefficient for conspicuity. Lesion size comparisons were assessed using the Spearman rank correlation. RESULTS: In 40 patients (ages 28.4-80.5, 51.9 years), there were 49 cancers. 10.1% of lesions were 1 cm or less and 26.5% of lesions were 2 cm or less. Each reader detected 49/49 cancers. Conspicuity scores ranged from 2 to 3, mean 2.9/3 for both readers (p = 0.47). Size on half-dose 3T DCE-MRI correlated with size on surgical pathology (r = 0.6, p = 0.03) while size on mammogram and ultrasound did not (r = 0.25, p = 0.46; r = 0.25, p = 0.42). CONCLUSION: All breast cancers in this cohort, as small as 0.4 cm, were seen on 3T DCE breast MRI with 0.05 mmol/kg dose of gadobutrol. |
| DOI | 10.1016/j.clinimag.2019.06.014 |
| PubMed ID | 31279989 |
| PubMed Central ID | PMC6893111 |